Abstract: Imidazole derivatives of the formula (1) or salts thereof, pharmaceuticals containing the derivatives or the salts, and intermediates for the synthesis of the derivatives or the salts (wherein R1 is lower alkyl; R2 is alkyl or aralkyl; and X1 is halogeno). These compounds exhibit G-CSF-like activities and can be substituted for G-CSF preparations.

Abstract: Imidazole derivatives of the formula (1) or salts thereof, pharmaceuticals containing the derivatives or the salts, and intermediates for the synthesis of the derivatives or the salts (wherein R1 is lower alkyl; R2 is alkyl or aralkyl; and X1 is halogeno). These compounds exhibit G-CSF-like activities and can be substituted for G-CSF preparations.

Abstract: Described is an azole derivative represented by the following formula (1): wherein, R1 represents a substituted phenyl group, R2 and R3 each represents a fluorine atom, an alkyl group or the like, and R4 represents an alkyl group, or salt thereof; and a medicament comprising the derivative or salt as an effective ingredient. The compound according to the present invention exhibits excellent antimycotic action and has good aqueous solubility.

Abstract: The invention relates to a process for preparing a difluoroacetophenone derivative (4) by alkylthionating a compound (1) into a compound (2) and reacting this compound with a compound (3). wherein X1 is Cl, Br or I, X2 and X3 are independently a halogen atom, H or perfluoroalkyl group, X4 is a halogen atom, R1 is an alkyl, aryl or aralkyl group, and R2 is methyl, ethyl or cyclopropyl group.

Abstract: Described is a triazole derivative represented by the formula (1): wherein R1 represents a hydrogen atom, a lower alkyl group or an aralkyl group, X1 and X2 are the same or different and each independently represents a hydrogen atom, a halogen atom or a halogenoalkyl and n stands for an integer of 0 to 2, or salt thereof; a preparation process of said compound and a pharmaceutical comprising said compound as an effective ingredient. The compound as described above has high antimycotic activity and is useful for the prevention and treatment of mammalian mycotic infections.

Abstract: Described is a triazole derivative represented by the formula (1): wherein R1 represents a hydrogen atom, a lower alkyl group or an aralkyl group, X1 and X2 are the same or different and each independently represents a hydrogen atom, a halogen atom or a halogenoalkyl and n stands for an integer of 0 to 2, or salt thereof; a preparation process of said compound and a pharmaceutical comprising said compound as an effective ingredient. The compound as described above has high antimycotic activity and is useful for the prevention and treatment of mammalian mycotic infections.

Abstract: Described is a triazole derivative represented by the formula (1): wherein R1 represents a hydrogen atom, a lower alkyl group or an aralkyl group, X1 and X2 are the same or different and each independently represents a hydrogen atom, a halogen atom or a halogenoalkyl and n stands for an integer of 0 to 2, or salt thereof; a preparation process of said compound and a pharmaceutical comprising said compound as an effective ingredient. The compound as described above has high antimycotic activity and is useful for the prevention and treatment of mammalian mycotic infections.

Abstract: Described is a triazole derivative represented by the formula (1): wherein R1 represents a hydrogen atom, a lower alkyl group or an aralkyl group, X1 and X2 are the same or different and each independently represents a hydrogen atom, a halogen atom or a halogenoalkyl and n stands for an integer of 0 to 2, or salt thereof; a preparation process of said compound and a pharmaceutical comprising said compound as an effective ingredient. The compound as described above has high antimycotic activity and is useful for the prevention and treatment of mammalian mycotic infections.

Abstract: Disclosed are SH-labeling reagents containing acridine compounds represented by the following formula (I): wherein A represents the following group: —(CH2)m1— or —(CH2)m2—Q—(CH2)n— in which Q represents a group —S+RX−—, a group —N+RR1X−— wherein R1 represents an alkyl group having 1 to 6 carbon atoms or an aryl group, a group wherein R2 and R3 may be the same or different and are each independently a group —(CH2)k— (k: a number of 1 to 3) or —O(CH2CH2O)l— (l: a number of 1 to 3), m1 stands for a number of 1 to 6, m2 denotes a number of 0 to 2, n means a number of 1 to 2; R represents an alkyl group having 1 to 6 carbon atoms or an aryl group; and X− represents an anion, or intermediates thereof; preparation processes of the acridine compounds; and methods for labeling analytes by using the compounds.

Abstract: Described is a triazole derivative represented by the formula (1): ##STR1## wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or an aralkyl group, X.sup.1 and X.sup.2 are the same or different and each independently represents a hydrogen atom, a halogen atom or a halogenoalkyl and n stands for an integer of 0 to 2, or salt thereof; a preparation process of said compound and a pharmaceutical comprising said compound as an effective ingredient.The compound as described above has high antimycotic activity and is useful for the prevention and treatment of mammalian mycotic infections.

Abstract: A compound having formula (2): ##STR1## wherein R represents hydrogen, a straight or branched C.sub.1-10 alkyl group, a C.sub.7-11 aralkyl group or a C.sub.2-10 carboacyl group and m stands for 1 to 5.

Abstract: Described is a triazole derivative represented by the formula (1): wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or an aralkyl group, X.sup.1 and X.sup.2 are the same or different and each independently represents a hydrogen atom, a halogen atom or a halogenoalkyl and n stands for an integer of 0 to 2, or salt thereof; a preparation process of said compound and a pharmaceutical comprising said compound as an effective ingredient.The compound as described above has high antimycotic activity and is useful for the prevention and treatment of mammalian mycotic infections.

Abstract: Substituted quinolone derivatives represented by the following formula: ##STR1## wherein R.sup.1 represents a substituted or unsubstituted (hetero)aryl group, R.sup.2 represents H or an alkoxycarbonyl, substituted aminocarbonyl, cyano or like group, and R.sup.3 and R.sup.4 each independently represent H or a substituted alkyl, aryl, amino or like group, and salts thereof; pharmaceuticals containing the same. These derivatives and salts have excellent anti-ulcer activities.

Abstract: Described is a triazole derivative represented by the formula (1): ##STR1## wherein R.sup.1 represents a lower alkyl group or an aralkyl group, R.sup.2 represents a hydrogen atom, a lower alkyl group, an aralkyl group or an acyl group, X.sup.1 and X.sup.2 are the same or different and each independently represents a hydrogen atom, a halogen atom or a trifluoromethyl group, n stands for an integer of 0 to 2 and m stands for an integer of 1 to 5, or salt thereof; and also a pharmaceutical comprising the derivative or salt thereof as an effective ingredient. The compound as described above has a high antimycotic activity and is useful for the prevention and treatment of mammalian mycotic infections.

Abstract: Described is a triazole derivative represented by the formula (1) or salt thereof, preparation process thereof, preparation intermediates represented by the formulas (2) and (3), and a pharmaceutical comprising the compound represented by the formula (1) or salt thereof. ##STR1## wherein n stands for 0, 1 or 2, X.sup.1 represents H or F and Y.sup.1 and Y.sup.2 each independently represents H, halogen or CF.sub.3.

Abstract: Described is a triazole derivative represented by the formula (1) or salt thereof, preparation process thereof, preparation intermediates represented by the formulas (2) and (3), and a pharmaceutical comprising the compound represented by the formula (1) or salt thereof. wherein n stands for 0, 1 or 2, X.sup.1 represents H or F and Y.sup.1 and Y.sup.2 each independently represents H, halogen or CF.sub.3.

Abstract: Disclosed are dithiolylidene acetamide derivatives represented by the following formula: ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different and each independently represent a hydrogen atom or an alkyl group, or salts thereof; and pharmaceuticals containing them as effective ingredients. The dithiolylidene acetamide derivatives and their salts show AGE formation inhibitory action and are useful as preventives and therapeutics for diabetic complications.

Abstract: Described is a triazole derivative represented by the formula (1) or salt thereof, preparation process thereof, preparation intermediates represented by the formulas (2) and (3), and a pharmaceutical comprising the compound represented by the formula (1) or salt thereof. ##STR1## wherein n stands for 0, 1 or 2, X.sup.1 represents H or F and Y.sup.1 and Y.sup.2 each independently represents H, halogen or CF.sub.3.

Abstract: Described is a triazole derivative represented by the formula (1): wherein R represents a hydrogen atom, an alkyl group, an aralkyl group or an acyl group, n stands for 0 to 2 and m stands for 1 to 5 or salt thereof, and a pharmaceutical containing the derivative or salt as an effective ingredient.

Abstract: The specification describes novel thiazinobenzimidazole derivatives represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2 and X represent a wide variety of substituent groups respectively. The above thiazinobenzimidazole derivatives may be prepared by reacting corresponding 2-hydroxymethyl thiazinobenzimidazole derivatives with corresponding reactive derivatives of carboxylic acid or halogenide or by reacting 2-p-toluenesulfonyloxymethyl-thiazinobenzimidazole derivatives with sodium azides, thiols, phenols or amines. The above thiazinobenzimidazole derivatives wherein X is OH may be prepared by reducing their corresponding 2-alkoxycarbonyl derivatives. Where X represents a p-toluenesulfonyloxy group, the thiazinobenzimidazole derivatives may be obtained by reacting corresponding 2-hydroxymethyl-thiazinobenzimidazole derivatives with p-toluenesulfonyl chloride.